Literature DB >> 8647993

Histology of hidradenitis suppurativa.

G B Jemec1, U Hansen.   

Abstract

BACKGROUND: Hidradenitis suppurativa is traditionally classified as a disease of the apocrine gland. However, different histologic descriptions exist.
OBJECTIVE: Our purpose was to describe prospectively the histopathologic characteristics of hidradenitis.
METHODS: We systematically described and classified 60 consecutive biopsy specimens from patients with hidradenitis and compared them with 33 specimens from clinically noninvolved regional controls.
RESULTS: A heterogeneous histologic picture was found. Apocrine glands were involved in a minority of the 60 specimens, 17 showed poral occlusion, 17 simple folliculitis without poral occlusion, 9 sinus tracts, 6 epithelial cyst, 5 abscess, 3 apocrinitis, 2 diffuse dermal inflammation, and 1 pyogenic granuloma and scarring. Secondary involvement of apocrine glands was found in 12% of all specimens, and secondary involvement of eccrine glands was found in 25%. Sinus tracts were found significantly more often in the presence of poral occlusion or epithelial cysts. Control specimens frequently revealed changes compatible with early stages of follicular involvement. Apocrine glands were observed significantly more often in the axillae than in the groin.
CONCLUSION: The clinical picture of hidradenitis suppurativa covers a broad histologic spectrum. This may help explain the therapeutic problems posed by this disease. The disease appears to be predominantly follicular, and apocrine glands appear to be primarily involved in only a minority of axillary lesions.

Entities:  

Mesh:

Year:  1996        PMID: 8647993     DOI: 10.1016/s0190-9622(96)90277-7

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  27 in total

1.  [Acne inversa].

Authors:  A Stein; G Sebastian
Journal:  Hautarzt       Date:  2003-02       Impact factor: 0.751

2.  Comorbidities of hidradenitis suppurativa (acne inversa).

Authors:  Sabine Fimmel; Christos C Zouboulis
Journal:  Dermatoendocrinol       Date:  2010-01

Review 3.  An Update on Medical Treatment Options for Hidradenitis Suppurativa.

Authors:  I E Deckers; E P Prens
Journal:  Drugs       Date:  2016-02       Impact factor: 9.546

4.  The Follicular Skin Microbiome in Patients With Hidradenitis Suppurativa and Healthy Controls.

Authors:  Hans Christian Ring; Jonathan Thorsen; Ditte M Saunte; Berit Lilje; Lene Bay; Peter Theut Riis; Niels Larsen; Lee O'Brien Andersen; Henrik V Nielsen; Iben M Miller; Thomas Bjarnsholt; Kurt Fuursted; Gregor Borut Jemec
Journal:  JAMA Dermatol       Date:  2017-09-01       Impact factor: 10.282

Review 5.  Surgical treatment of hidradenitis suppurativa: case series and review of the literature.

Authors:  Shahzad Ather; David S Y Chan; David J Leaper; Keith G Harding
Journal:  Int Wound J       Date:  2006-09       Impact factor: 3.315

Review 6.  The critical role of macrophages in the pathogenesis of hidradenitis suppurativa.

Authors:  Ahmed Shah; Raed Alhusayen; Saeid Amini-Nik
Journal:  Inflamm Res       Date:  2017-06-27       Impact factor: 4.575

Review 7.  Medical and Surgical Treatment of Hidradenitis Suppurativa: A Review.

Authors:  Nicolò Scuderi; Ambra Monfrecola; Luca Andrea Dessy; Gabriella Fabbrocini; Matteo Megna; Giuseppe Monfrecola
Journal:  Skin Appendage Disord       Date:  2017-03-21

8.  Successful Treatment of Recalcitrant Hidradenitis Suppurativa with Adalimumab.

Authors:  Ian Gorovoy; Adar Berghoff; Laura Ferris
Journal:  Case Rep Dermatol       Date:  2009-10-27

Review 9.  Hidradenitis suppurativa/Acne inversa: an endocrine skin disorder?

Authors:  Ioannis Karagiannidis; Georgios Nikolakis; Robert Sabat; Christos C Zouboulis
Journal:  Rev Endocr Metab Disord       Date:  2016-09       Impact factor: 6.514

10.  Surgical approach to extensive hidradenitis suppurativa in the perineal/perianal and gluteal regions.

Authors:  Emre Balik; Tunc Eren; Türker Bulut; Yilmaz Büyükuncu; Dursun Bugra; Sümer Yamaner
Journal:  World J Surg       Date:  2009-03       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.